October 4, 2021 News by Steve Bryson, PhD JC Virus Mutations May Predict Rare Brain Infection Linked to Tysabri Mutations in the John Cunningham virus may serve as an early predictor for a rare brain infection in multiple sclerosis patients receiving Tysabri (natalizumab), a study suggests. However, more research is required to investigate the specific mutations in the viral VP1 gene, and validate the risk of the…
January 7, 2019 News by Santiago Gisler Biogen Starts Phase 3b Trial to Evaluate Tysabri Extended Interval Dosing in RRMS Patients Biogen announced the start of a global Phase 3b clinical trial to evaluate the efficacy and safety of extended interval dosing (EID) with Tysabri (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS). Results of the six-week dosing interval will be compared with the approved standard interval dosing…
February 9, 2018 Columns by Ed Tobias Good News for Tysabri Users Who Are JCV Positive One of the many disease-modifying therapies (DMTs) that I’ve been on over the many years of my treatment for MS is Tysabri (natalizumab). It worked well, holding the progression of my MS at bay for the several years that I received the infusions. I’d probably still be on it…
August 9, 2016 News by InĆŖs Martins, PhD Tysabri’s Success in Impairing the Immune System in RRMS May Be Source of Its Problems Although Tysabri (natalizumab) is a highly effective in treatingĀ patients with relapsing-remitting multiple sclerosis (RRMS), some may developĀ progressive multifocal leukoencephalopathy (PML). According to a new study,Ā this occurs because TysabriĀ impairs immune surveillance in the central nervous system and reactivates the latentĀ John Cunningham polyomavirus (JCV). The study, “Natalizumab Affects…
May 24, 2016 News by Patricia Silva, PhD JC Virus Carries a Mutation in MS Patients That Amplifies Brain Disease Known as PML A mutation in aĀ mouse modelĀ of the John Cunningham (JC) virus, which causes progressive multifocal leukoencephalopathy (PML), allows the virus to evade the host immune responses in people with multiple sclerosis (MS),Ā according to a study into the mechanisms of PML. Infection with the JC virus most often passes unnoticed in healthy…
August 10, 2014 News by BioNews Staff JCV Virus May Be Missed in Patients Who Take Popular MS Drug, According To Study Multiple sclerosisĀ (MS) patients who are prescribedĀ TysabriĀ have an increased risk to develop the rare, often fatal infection of the brain called progressive multifocal leukoencephalopathy (PML), according to a recent study. PML is caused by a common virus that infects blood cells and can be mobilized by popular RRMS drug Natalizumab,…